February 2022 in “International Journal of Research in Dermatology” The authors provide an overview of using topical minoxidil to manage female pattern hair loss in Indian clinical practice, emphasizing its significance as the main treatment method.
16 citations
,
June 2021 in “Journal of Dermatological Treatment” This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.
April 2020 in “Dermatology and therapy” In this study, the novel 5% minoxidil formulation significantly increased scalp hydration and decreased redness in Indian men with androgenetic alopecia compared to alcohol-based formulations.
30 citations
,
January 2019 in “International Journal of Trichology” This study observed that androgenetic alopecia significantly impacts the quality of life in males, with personal relationships being notably affected, based on Dermatology Life Quality Index and hair-specific Skindex-29 assessments.
8 citations
,
January 2019 in “International Journal of Trichology” This review discusses dermatologists' expert opinions on choosing effective and safe treatments for managing androgenetic alopecia, but it reports no new research findings.
36 citations
,
June 2018 in “Journal of Dermatology” This article updates Japanese guidelines for diagnosing and treating male and female-pattern hair loss, recommending specific drugs and therapies while advising against certain treatments for female-pattern hair loss.
5 citations
,
April 2018 in “Journal of Cosmetic Dermatology” This study found that the new minoxidil formulation, DC0120, was noninferior to the marketed product ALOSTIL® in promoting hair growth for men with androgenetic alopecia over 16 weeks.
145 citations
,
November 2017 in “Journal of The European Academy of Dermatology and Venereology” This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.
29 citations
,
November 2012 in “Journal of The European Academy of Dermatology and Venereology” This review discusses the development of an algorithmic guideline for treating androgenetic alopecia in Asian patients, using the BASP classification to address limitations of previous guidelines, and reports no clinical results.
152 citations
,
April 2012 in “Recent Patents on Inflammation & Allergy Drug Discovery” This review describes minoxidil's hair regrowth mechanism and discusses dermatological applications, but reports no new clinical results, emphasizing the need for regular use and addressing allergic reactions.
142 citations
,
August 2007 in “Journal of The American Academy of Dermatology” This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.
123 citations
,
February 2002 in “Journal of The American Academy of Dermatology” Minoxidil can cause skin allergy; use alternative solvents or treatments if allergic.
192 citations
,
March 1998 in “British Journal of Dermatology” This study found that minoxidil significantly increases VEGF mRNA and protein expression in dermal papilla cells, suggesting a role in enhancing hair follicle vascularization in androgenetic alopecia.
57 citations
,
January 1980 in “Journal of Cardiovascular Pharmacology” Minoxidil treats high blood pressure and side effects can be managed.